Class-sparing regimens for initial treatment of HIV-1 infection.
about
Does HAART efficacy translate to effectiveness? Evidence for a trial effectDual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsThe 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected KoreansEfavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsHIV protease inhibitors: a review of molecular selectivity and toxicityIllustration of a measure to combine viral suppression and viral rebound in studies of HIV therapyHIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmissionTiming the emergence of resistance to anti-HIV drugs with large genetic barriersPrevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter CohortPolymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimenHIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirsMinor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failureLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensRole of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failureFirst line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyFactors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South AfricaEffectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed ViremiaPregnancy and virologic response to antiretroviral therapy in South AfricaChallenges in initiating antiretroviral therapy in 2010.Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs.What's new for antiretroviral treatment in women with HIVNanotechnology and HIV: potential applications for treatment and prevention.CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, HaitiNew therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral TherapyAssociation between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG).Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.Efavirenz in the therapy of HIV infection.The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.Growth among HIV-infected children receiving antiretroviral therapy in Dar es Salaam, Tanzania.Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011.Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTITransmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Using administrative claims data to estimate virologic failure rates among human immunodeficiency virus-infected patients with antiretroviral regimen switches.Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data
P2860
Q21135313-A322D8A4-7F7C-4E54-9F21-57B7A55A50ABQ26768591-0B2EC6AA-9764-42E3-8EF0-F16AB33BE84FQ26781379-1E176FB2-58E8-4BF9-8EFD-0F788D3A5946Q28081266-49020EA5-EEC9-41E0-9FDD-9D4B11C0F74EQ28082749-753A4021-1390-472E-AE29-04E6F91FCE4AQ28385909-FAF34992-125B-4902-A39A-5627C979BE6AQ28473637-9381EE92-EF5C-4498-AE84-72059EF48772Q28474857-963E0E28-0BFA-4F20-A1F7-098936C96B9FQ28475698-BD924390-3AA8-4C94-A193-7697AC482D70Q28477151-A236DB0F-721B-401B-9FFC-C9E7CB8D91B7Q28477500-37F1EAF0-AED0-4B3C-A00D-9E4C9439E317Q28478779-61CB03CC-FF23-4B8C-ACE4-DBC19DE0EE48Q28485321-C6F8293D-BFD6-4A37-8095-8258FBEBCE4DQ28533767-4A9799CC-DD09-4F23-A909-2A57BE923086Q28538326-2FE4C3A8-44EA-4271-9E5B-4F721821F695Q28546698-4EAAD2C4-E69F-4D57-934F-BD20876EABFCQ28548630-2A9FD0B4-F552-411F-8292-6F00688F6B3EQ28741879-A41B77CA-6E83-4746-AA29-62D34680EF16Q30227046-2960A33E-BD37-467A-91A7-D5686A858358Q30386701-633CD980-05CD-4482-A3B3-7DC5BFA8CE72Q30391322-E0A9EA86-3E3A-4F1F-9A18-DE8974C93D6AQ30393980-CC7AD8B3-A060-463F-8907-EEB1AA43F776Q30438405-8108E5A7-23A9-453E-91C7-CB78A75D95FDQ30578338-5A9E1279-58EE-4B3B-81FC-F226B545717CQ30609066-4B2F4074-BFDF-4980-9045-779AF028BE5EQ30834094-96829EC3-00F9-4B25-A33F-C50652F0C916Q31037300-CCFD9D14-DCC1-41D2-B881-AB715E6E45F4Q31159582-BA4C0A10-7E98-44A8-ACEB-8CD0C39A52D4Q33355997-74F6D92A-39A4-4DBB-B4C0-9771D0ABD17CQ33607011-AF6F4CD7-4E0A-4ACD-9428-2D9FD0498FE1Q33681279-7C90E306-2EE7-4335-91D1-C3D490D7ECA4Q33695680-59F7F716-9469-4E44-86E2-0A47F580D8A5Q33767281-3C608BDB-8FA4-41F8-943E-6DDE4F1B2702Q33775397-2930FC12-1B67-4498-9209-C7749F6F375CQ33793720-490F92A3-35A7-4AAE-8E1B-6276E46DB199Q33803473-CF4DE80E-1889-40DA-BD15-B39178B5C30BQ33814896-A9B44D81-0674-4D08-9822-258DBD4FC12DQ33872810-C0C84158-297C-47AD-890B-3EDB80E154DEQ33879444-ED308857-CEE9-4A2C-82F7-99A0C1C2FDAAQ33891656-FDA5283F-527D-4D78-8F42-0843A82641B3
P2860
Class-sparing regimens for initial treatment of HIV-1 infection.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Class-sparing regimens for initial treatment of HIV-1 infection.
@en
Class-sparing regimens for initial treatment of HIV-1 infection.
@nl
type
label
Class-sparing regimens for initial treatment of HIV-1 infection.
@en
Class-sparing regimens for initial treatment of HIV-1 infection.
@nl
prefLabel
Class-sparing regimens for initial treatment of HIV-1 infection.
@en
Class-sparing regimens for initial treatment of HIV-1 infection.
@nl
P2093
P2860
P50
P356
P1476
Class-sparing regimens for initial treatment of HIV-1 infection.
@en
P2093
A Gregory DiRienzo
AIDS Clinical Trials Group Study A5142 Team
Barbara Brizz
James F Rooney
John W Mellors
Karin L Klingman
Kevin W Garren
Lynne Peeples
Richard Haubrich
Sharon A Riddler
P2860
P304
P356
10.1056/NEJMOA074609
P407
P577
2008-05-01T00:00:00Z